Drug intelligence / Profile preview

KBD081

Development stage: Preclinical
Lead developer: Kangbaida

Overview

KBD081 is an early-stage therapeutic candidate developed by Kangbaida (Sichuan) Biomedical Technology, a wholly-owned subsidiary of Chengdu Baiyu Pharmaceutical. It is being investigated for applications in anti-aging, weight loss, and muscle gain. The exact biological target, mechanism of action, and molecular modality of KBD081 have not been publicly disclosed by the developer.

Targets

LANCL2 (Lanthionine synthetase C-like protein 2)

Beyond the preview

Go deeper on KBD081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBD081.

Explore the full profile